ITINERARIO 5: PATOLOGÍA DIGESTIVA

JUEVES 24 DE OCTUBRE

VIERNES 25 DE OCTUBRE

BIBLIOGRAFIA

• Guarner F. Microbiota intestinal y enfermedades inflamatorias del intestino. Gastroenterol Hepatol. 2011; 34 (3):147-54.
  doi:10.1016/j.gastrohep.2010.11.009.
• Marco-Martínez J, Barba-Martín R, Plaza-Canteli S, Canora-Lebrato J, Méndez-Baillón M, de Miguel-Yanes JM, et al. Infección por Clostridium difficile en el período 2005-2010 en los Servicios de Medicina Interna españoles: el peso de la enfermedad.
  Enferm Infecc Microbiol Clin. 2015; 33 (1):16–21.
• Diez-Domingo J, Suriñach NL, Malé Alcalde S, Betegón L, Largeron N, Trichard M.
  Burden of paediatric Rotavirus Gastroenteritis (RVGE) and potential benefits of a universal Rotavirus vaccination programme with a pentavalent vaccine in Spain.
  BMC Public Health 2010, 10: 469
• Kotloft KL, Nataro JP, Blackwelder WC, Nasrim D, Farag TH, Pancgalingam S, et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study.
  Lancet 2013; 382: 209–22
  doi: 10.1016/S0140-6736(13)60844-2.
• Sala Farré MR, Osorio Sánchez D, Arias Varela C, Simó Sanahuja M, Recasens Recasens A, Pérez Jové J. Aspectos epidemiológicos y carga asistencial de gastroenteritis agudas por Campylobacter y Salmonella.
  Med Clin (Barc). 2015; 145 (7): 294–97
• Novel Targeted Therapies for IBD
• Environmental triggers in IBD: a review of progress and evidence
• Integrating Omics: The Future of IBD?
• IBD prevalence in Lothian, Scotland, derived by capture–recapture methodology
• The current state of the art for biological therapies and new small molecules in inflammatory bowel disease

• Simposio 7. Dispepsia: ¿Trastorno gastrointestinal funcional u orgánico?

  • Test and treat for Helicobacter pylori (HP) in dyspepsia. Quick reference guide for primary care: For consultation and local adaptation. Public Health England, October 2016.
  • Rivero Fernández M et al. Dolor originado en la pared abdominal: una alternativa diagnóstica olvidada. Gastroenterol Hepatol. 2007 Apr;30(4):244-50.
  • Suchy FJ et al. NIH Consensus Development Conference Statement: Lactose Intolerance and Health. NIH Consens State Sci Statements. 2010 Feb 22–24; 27(2):1–27.
  • Protocolo de diagnóstico de la Hipolactasia / Intolerancia a la lactosa / Malabsorción de lactosa en práctica clínica. Grupo de trabajo de la SEPD en hipolactasia / intolerancia a la lactosa / malabsorción de lactosa. Coordinadores: F Argüelles Arias, F Carballo Álvarez, E Domínguez Muñoz. Publicado por la Sociedad Española de Patología Digestiva (SEPD).
  • Fassio F et al. Lactose Maldigestion, Malabsorption, and Intolerance: A Comprehensive Review with a Focus on Current Management and Future Perspectives. Nutrients. 2018 Nov 1;10(11). pii: E1599.
  • Gisbert JP et al. IV Conferencia Española de Consenso sobre el tratamiento de la infección por Helicobacter pylori. Gastroenterol Hepatol. 2016 Dec;39(10):697-721.
  • Malfertheiner P et al. Management of Helicobacter pylori infection- the Maastricht IV/Florence Consensus Report. Gut 2012 May;61(5):646-64.
  • Carethers JM, Braun J, Sands BE. Genetics, Genetic Testing, and Biomarkers of Digestive Diseases. Gastroenterology. 2015; 149:1131-3.
  • Talebi Bezmin Abadi A. The Helicobacter pylori dupA: A Novel Biomarker for Digestive Diseases. Front Med (Lausanne). 2014; 28:1-13.
  • Agréus L, Kuipers EJ, Kupcinskas L, Malfertheiner P, Di Mario F, Leja M, Mahachai V, Yaron N, van Oijen M, Perez Perez G, Rugge M, Ronkainen J, Salaspuro M, Sipponen P, Sugano K, Sung J. Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers. Scand J Gastroenterol. 2012; 47:136-47.

• Simposio 10. Dolor abdominal: Enfermedad Inflamatoria Intestinal y trastornos relacionados con el gluten

  • Laserna-Mendieta EJ & Lucendo AJ.Faecal calprotectin in inflammatory bowel diseases: a review focused on meta-analyses and routine usage limitations. Clin Chem Lab Med. 2019 Aug 27;57(9):1295-1307. doi: 10.1515/cclm-2018-1063.
  • Salvador-Martín S et al. Genetic predictors of long-term response and trough levels of infliximab in Crohn's disease. Pharmacol Res. 2019 Oct 9:104478. doi: 10.1016/j.phrs.2019.104478.
  • Laserna-Mendieta EJ et al. Comparison of a new rapid method for the determination of adalimumab serum levels with two established ELISA kits. Clin Chem Lab Med. 2019 May 14. pii: /j/cclm.ahead-of-print/cclm-2019-0202/cclm-2019-0202.xml. doi: 10.1515/cclm-2019-0202.

BOLETIN DE NOTICIAS